Redirecting anti-viral CTL against cancer cells by surface targeting of monomeric MHC class I-viral peptide conjugated to antibody fragments

Cancer immunity

Bruno Robert²  Immanuel Luescher¹  Philippe Guillaume³ 

[1] Ludwig Institute for Cancer Research, Lausanne Branch, CH-1066 Epalinges, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, CH-1066 Epalinges, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, CH-1066 Epalinges, Switzerland;Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, SwitzerlandThese authors contributed equally to this workInstitute of Biochemistry, University of Lausanne, CH-1066 Epalinges, SwitzerlandInstitute of Biochemistry, University of Lausanne, CH-1066 Epalinges, SwitzerlandThese authors contributed equally to this workThese authors contributed equally to this workInstitute of Biochemistry, University of Lausanne, CH-1066 Epalinges, SwitzerlandThese authors contributed equally to this work;Multidisciplinary Oncology Center, University Hospital (CHUV), CH-1011 Lausanne, SwitzerlandThese authors contributed equally to this workMultidisciplinary Oncology Center, University Hospital (CHUV), CH-1011 Lausanne, SwitzerlandMultidisciplinary Oncology Center, University Hospital (CHUV), CH-1011 Lausanne, SwitzerlandThese authors contributed equally to this workThese authors contributed equally to this workMultidisciplinary Oncology Center, University Hospital (CHUV), CH-1011 Lausanne, SwitzerlandThese authors contributed equally to this work

关键词: tumor antibodies;    Fab immunoglobulins;    MHC class I;    immunoconjugates;    cultured tumor cells;    cytotoxic T-lymphocytes;    immunotherapy;   

DOI  :  

学科分类：肿瘤学

来源: Cancer immunity

【 授权许可】

Unknown